ChiCTR2600121844 版本V1.0 版本创建时间2026/04/03 17:36:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600121844 

最近更新日期:

Date of Last Refreshed on:

2026-04-03 17:36:17 

注册时间:

Date of Registration:

2026-04-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

湖北省结核病高负担地区结核病患者流行病学调查

Public title:

Epidemiological Investigation of Tuberculosis Patients in High-Burden Areas of Tuberculosis in Hubei Province

注册题目简写:

English Acronym:

研究课题的正式科学名称:

湖北省结核病高负担地区结核病患者流行病学调查

Scientific title:

Epidemiological Investigation of Tuberculosis Patients in High-Burden Areas of Tuberculosis in Hubei Province

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周丽平 

研究负责人:

周丽平 

Applicant:

Liping Zhou 

Study leader:

Liping Zhou 

申请注册联系人电话:

Applicant telephone:

+86 27 87652109

研究负责人电话:

Study leader's
telephone:

+86 27 87652268

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

372008131@qq.com

研究负责人电子邮件:

Study leader's E-mail:

372008131@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市洪山区卓刀泉北路35号

研究负责人通讯地址:

湖北省武汉市洪山区卓刀泉北路35号

Applicant address:

35 Zuodaoquan North Road, Hongshan District, Wuhan, Hubei 430079, China

Study leader's address:

35 Zuodaoquan North Road, Hongshan District, Wuhan, Hubei 430079, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

湖北省疾病预防控制中心

Applicant's institution:

Hubei Provincial Center for Disease Control and Prevention

研究负责人所在单位:

湖北省疾病预防控制中心

Affiliation of the Leader:

Hubei Provincial Center for Disease Control and Prevention

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-032-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湖北省疾病预防控制中心(湖北省预防医学科学院)伦理审查委员会

Name of the ethic committee:

Hubei Provincial Center for Disease Control and Prevention Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-24 00:00:00

伦理委员会联系人:

沈恒

Contact Name of the ethic committee:

Shen Heng

伦理委员会联系地址:

湖北省武汉市洪山区卓刀泉北路35号

Contact Address of the ethic committee:

35 Zuodaoquan North Road, Hongshan District, Wuhan, Hubei 430079, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 87652129

伦理委员会联系人邮箱:

Contact email of the ethic committee:

277059573@qq.com

研究实施负责(组长)单位:

湖北省疾病预防控制中心

Primary sponsor:

Hubei Provincial Center for Disease Control and Prevention

研究实施负责(组长)单位地址:

湖北省武汉市洪山区卓刀泉北路35号

Primary sponsor's address:

35 Zuodaoquan North Road, Hongshan District, Wuhan, Hubei 430079, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

湖北省疾病预防控制中心

具体地址:

湖北省武汉市洪山区卓刀泉北路35号

Institution
hospital:

Hubei Provincial Center for Disease Control and Prevention

Address:

35 Zuodaoquan North Road, Hongshan District, Wuhan, Hubei 430079, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-Selected Project (Self-Financed)

研究疾病:

结核病  

Target disease:

tuberculosis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

通过开展结核病高负担地区结核患者流行病学调查,掌握恩施州结核病患者的社会人口学与流行特征;通过全基因组测序,系统解析本地区结核分枝杆菌遗传结构,揭示其传播模式;对利川市结核病患者密切接触者进行主动筛查与健康监测,评估高风险人群结核病早发现的效果。  

Objectives of Study:

(1) investigate the sociodemographic and epidemiological characteristics of tuberculosis (TB) patients in a high-burden area of Enshi Prefecture, and to analyze the genetic structure and transmission dynamics of local Mycobacterium tuberculosis strains; (2) implement and assess the outcome of active screening and health monitoring for early TB detection among close contacts of patients in Lichuan City.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.结核病患者符合中华人民共和国卫生行业标准肺结核诊断标(WS288-2017),包括初治和复治患者; (2)成功分离培养结核分枝杆菌菌株,并完成测序。

Inclusion criteria

1. Tuberculosis patients met the diagnostic criteria of the People's Republic of China Health Industry Standard for Pulmonary Tuberculosis (WS 288-2017), including both new and retreatment cases; 2. Mycobacterium tuberculosis strains were successfully isolated and cultured, with sequencing completed.

排除标准:

1.培养污染或未成功分离出结核分枝杆菌; (2)被鉴定为非结核分枝杆菌; (3)建库失败或测序深度不足以满足变异分析要求。

Exclusion criteria:

1. Culture contamination or failure to successfully isolate Mycobacterium tuberculosis; 2. Identification as nontuberculous mycobacteria (NTM); 3. Failure in library preparation or insufficient sequencing depth for reliable variant analysis.

研究实施时间:

Study execute time:

From 2025-08-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-06 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

1250

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

湖北省疾病预防控制中心 

单位级别:

无 

Institution
hospital:

Hubei Provincial Center for Disease Control and Prevention

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

SNP分型

指标类型:

主要指标

Outcome:

Snp typing

Type:

Primary indicator

测量时间点:

全基因组测序之后

测量方法:

全基因组测序

Measure time point of outcome:

after whole genome sequencing

Measure method:

whole genome sequencing

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

痰标本

组织:

Sample Name:

Sputum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录和结核病信息管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record and tuberculosis information management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-03 17:36:17